GlassScriptPhysician profile
Duangchai Narawong
NPI 1750376034
$3,989.77
in general payments reported to CMS, 2019-2025
24 companies · $687 in 2025
The $687 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $509 · 2021: $304 · 2022: $439 · 2023: $839 · 2024: $858 · 2025: $687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,383.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $723.01 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Supernus Pharmaceuticals, INC. | $642.83 | 2020-2022 | |
| Neurelis, INC. | $393.03 | 2022-2025 | Valtoco |
| Jazz Pharmaceuticals INC. | $303.03 | 2022-2025 | Epidiolex |
| Livanova USA, INC. | $280.30 | 2022-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Sk Life Science, INC. | $266.24 | 2021-2024 | Xcopri |
| Immedica Pharma US, INC. | $172.84 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $162.12 | 2023-2025 | Koselugo |
| Biogen, INC. | $145.00 | 2024-2025 | Spinraza, Skyclarys |
| Mallinckrodt Enterprises LLC | $136.72 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $121.14 | 2023-2024 | Fycompa |
| Greenwich Biosciences, INC. | $119.61 | 2019 | |
| Intrabio INC | $68.67 | 2025 | Aqneursa |
| Sunovion Pharmaceuticals INC. | $66.97 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $63.70 | 2025 | Ajovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zogenix INC. | $59.45 | 2021 | |
| Acadia Pharmaceuticals INC | $53.27 | 2023 | Daybue |
| Aquestive Therapeutics, INC. | $51.97 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $43.67 | 2023 | Lyvispah |
| Azurity Pharmaceuticals, INC. | $38.37 | 2024 | Zonisade |
| Pyros Pharmaceuticals, INC. | $22.53 | 2024 | Vigpoder |
| Aucta Pharmaceuticals, INC. | $21.85 | 2025 | Motpoly Xr |
| Baxter Healthcare | $17.55 | 2022 | |
| Biomarin Pharmaceutical INC. | $15.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Duangchai Narawong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.